IFNAR2
Interferon alpha/beta receptor 2
As of the edition of 20 October 2026, IFNAR2 (interferon alpha/beta receptor 2, UniProt P48551) has 13 drugs tested at it and 8 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P48551
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 9
- Disease areas
- Infections; Digestive system; Cancer; Immune system; Nervous system; Urinary and reproductive; Blood and lymph; Skin and connective tissue
- Registered trials of its drugs
- 980
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 11 |
| Active | 2 |
| Total | 13 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Peginterferon alfa-2a | Marketed | Phase 4 | Ended 2014 |
| Peginterferon alfa-2b | Marketed | Phase 4 | Ended 2013 |
| Interferon alfa-2b | Marketed | Phase 4 | Ended 1998 |
| Interferon beta-1a | Marketed | Phase 4 | Ended 2008 |
| Interferon beta-1b | Marketed | Phase 4 | Ended 2005 |
| Interferon | Marketed | Phase 4 | none listed |
| Ropeginterferon alfa-2b | Marketed | Phase 4 | Ends 2033 |
| Interferon alfa-2a | Marketed | Phase 3 | Ended 1998 |
| Peginterferon beta-1a | Marketed | Phase 4 | Ended 2026 |
| Interferon beta | Active | Phase 3 | none listed |
| Albinterferon alfa-2b | Active | Phase 2 | none listed |
| Interferon alfacon-1 | Marketed | Phase 4 | Ended 2009 |
12 of 13 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 8 |
| Total on the list | 8 |